Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT...
Read more
Latest News
Category: Clinical
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT...
Read more
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in...
Read more
Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American...
Read more
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product...
Read more
Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for...
Read more
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma...
Read more
Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,...
Read more
Telix Pharmaceuticals Limited is pleased to announce the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in...
Read more
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at...
Read more
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical...
Read more